TipRanks
Go Ultimate55% OFF

Indaptus Therapeutics (INDP) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Tislelizumab, Decoy20Pancreatic Adenocarcinoma, Msi-H Cancer, Solid Tumor, Adult, Uc (Urothelial Cancer), Hcc - Hepatocellular Carcinoma, Crc (Colorectal Cancer), Nsclc Non-Small Cell Lung Cancer, Squamous Cell Cancer Of The Head And Neckphase1AndPhase2RecruitingStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsNov 18, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Indaptus Therapeutics, Inc. (INDP) have in its pipeline
Indaptus Therapeutics INDP is currently developing the following drugs: Tislelizumab, Decoy20. These drug candidates are in various stages of clinical development as the company works toward FDA approval.